A multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose safety, tolerability, reactogenicity, and pharmacokinetic study of bapineuzumab (AAB 001) administered subcutaneously in subjects with mild to moderate AD.

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose safety, tolerability, reactogenicity, and pharmacokinetic study of bapineuzumab (AAB 001) administered subcutaneously in subjects with mild to moderate AD.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2013

At a glance

  • Drugs Bapineuzumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Aug 2012 Trial status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov record (Extension trial; NCT00916617).
    • 06 Aug 2012 Trial status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov record (Extension trial; NCT00916617).
    • 22 Jun 2012 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record (Extension trial; NCT00916617).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top